Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New insulin fiasp tested in everyday diabetes care

NCT ID NCT03987802

Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how safe and effective Fiasp, a faster-acting mealtime insulin, is for people with type 1 or type 2 diabetes in everyday life. 42 adults used Fiasp as prescribed by their doctor for about 6 months. Researchers tracked side effects and blood sugar control to see how the drug performs outside of a controlled trial.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Fiasp (faster-acting insulin aspart)
What this could lead to
If successful, this study could confirm that Fiasp is safe and effective for daily diabetes management in real-world settings.
What could go wrong
This is a small, non-interventional study with only 42 participants, so results may not apply to everyone. As with any insulin, there is a risk of low blood sugar (hypoglycemia).

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

42 people

The number who actually took part.

Started

Jan 2021

Finished

Jun 2022

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with diabetes mellitus (type 1 and type 2) under routine clinical practice in India.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study. * Male or female, age equal to or above 18 years at the time of signing the informed consent. * Patients diagnosed with diabetes mellitus. * Patients scheduled to start treatment with Fiasp® based on the clinical judgement of their treating physician. Exclusion Criteria: * Known or suspected hypersensitivity to study product(s) or related products. * Patients on or likely to use insulin pump therapy during the study period * Previous participation in this study. Participation is defined as having given signed informed consent. * Mental incapacity, unwillingness or language barriers hindering adequate understanding or cooperation. * Participation in any clinical study of an approved or non-approved investigational medicinal product within 1 month before treatment start. * Any disorder which in the opinion of the treating physician may jeopardise the patient's safety or compliance with the protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus type 2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus type 1 diabetes mellitus 1 type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus type 2 Diabetes mellitus, type 1

Contacts and locations

Locations

  • AMRI Hospitals, Dhakuria

    Kolkata, West Bengal, 700029, India

  • All India Institute of Medical Sciences (AIIMS), Bhubaneswar

    Khurda, Odisha, 751019, India

  • Apollo Hospital Jubilee Hills, Hyderabad

    Hyderabad, Telangana, 500033, India

  • Apollo Hospital, Navi Mumbai

    Mumbai, Maharashtra, 400614, India

  • Apollo Multispeciality Hospital, Kolkata

    Kolkata, West Bengal, 700054, India

  • Arthur Asirvatham hospital,

    Madurai, Tamil Nadu, 625 020, India

  • Aster Medcity

    Kochi, Kerala, 682027, India

  • CARE Hospitals

    Hyderabad, Andhra Pradesh, 500001, India

  • Calcutta Medical College

    Kolkata, West Bengal, 700073, India

  • Dr B L Kapur Memorial Hospital

    New Delhi, 110055, India

  • Excel Endocrine Centre

    Kolhāpur, Maharashtra, 416008, India

  • Gandhi Hospital & Medical college

    Hyderabad, Telangana, 500003, India

  • Jothydev's Diabetes & Research Center

    Thriruvananthapuram, 695 032, India

  • Karnataka Institute of Endocrinology & Research

    Bengaluru, Karnataka, 560069, India

  • Kerala Institute of Medical Sciences

    Trivandrum, Kerala, 695029, India

  • Kg Hospital and Post Graduate Medical Institute

    Coimbatore, Tamil Nadu, 641018, India

  • Life Care Hospital and Research Centre

    Bangalore, Karnataka, 560092, India

  • Malabar Institute of Medical Sciences Ltd,

    Calicut, Kerala, 673016, India

  • Max Super Speciality Hospital, Ghaziabad

    Ghaziabad, Uttar Pradesh, 201012, India

  • Max Super Speciality Hospital, Mohali

    Mohali, Punjab, 160055, India

  • Max Super Speciality Hospital, Saket

    New Delhi, National Capital Territory of Delhi, 110017, India

  • Medanta Lucknow Hospital

    Lucknow, Uttar Pradesh, 226030, India

  • Mysore Medical College and Research Institute

    Mysore, Karnataka, 570001, India

  • Osmania General Hospital

    Hyderabad, Telangana, 500012, India

  • PGIMS Rohtak

    Rohtak, Haryana, 124001, India

  • Post Graduate Institute of Medical Education & Research

    Chandigarh, Punjab, 160012, India

  • Pranav Diabetes Centre

    Bangalore, India

  • Regency Hospital

    Kanpur, Uttar Pradesh, 208006, India

  • Santokba Durlabhji Memorial Hospital

    Jaipur, Rajasthan, India

  • Siddhi Hospital And Laparoscopy Center Pvt Ltd

    Pune, Maharashtra, 411043, India

  • Sir Ganga Ram Hospital-Cardiology

    New Delhi, 110060, India

  • TOTALL Diabetes Hormone Institute

    Indore, Madhya Pradesh, 452010, India

  • Unique Hospital

    Surat, Gujarat, 395002, India

  • Vijayratna Diagnostic & Scientific Obesity Clinic

    Ahmedabad, Gujarat, 380007, India

  • Zandra Healthcare Pvt Ltd

    Mumbai, Maharashtra, 400058, India

  • chelleram Diabetes Institute

    Pune, Maharashtra, 411021, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.